Glial modulators as novel therapeutics for comorbid pain and opioid use disorder
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Elizabeth K C Schwartz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Chronic Pain, Analgesics, Opioid, Neuroglia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: NIDA NIH HHS, VISN 1 MIRECC, National Institute of Development Administration.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Chronic pain and opioid use disorder (OUD) are major public health problems, with rising opioid‐related overdose deaths linked to increased opioid prescriptions for pain management. Novel treatment approaches for these commonly comorbid disorders are needed. Growing evidence supports a role for glial activation for both chronic pain and substance use disorders, including OUD. This review provides an overview of glial modulators as a novel treatment approach for comorbid pain and OUD. We aim to synthesize clinical studies investigating the efficacy of glial modulators in treating these comorbid disorders. We conducted a literature search of PubMed and Google Scholar databases in October 2023 to identify relevant clinical trials. The included studies varied in terms of patient population, study methodology and outcomes assessed, and were often limited by small sample sizes and other methodological issues. Additionally, several glial modulators have yet to be studied for chronic pain and OUD. Despite these limitations, these studies yielded positive signals that merit further investigation. Both chronic pain and OUD remain significant public health problems, with many treatment challenges. Glial modulators continue to hold promise as novel therapeutics for comorbid pain and OUD, given positive indications that they can improve pain measures, and reduce addiction‐related outcomes. As our understanding of the mechanisms underlying the contributions of glial modulators to pain and addiction behaviours deepens, we will be better equipped to identify more specific therapeutic targets for chronic pain and OUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
- VA Connecticut Healthcare System, West Haven, Connecticut, USA.
- Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, Connecticut, USA.
ORCID-Profile: Elizabeth K C Schwartz, Mehmet Sofuoglu
Förderung
- NIDA NIH HHS
- VISN 1 MIRECC
- National Institute of Development Administration
Zitieren
APA
Schwartz, E. K. C., De Aquino, J. P., & Sofuoglu, M. (2024). Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16094
Vancouver
Schwartz EKC, De Aquino JP, Sofuoglu M. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16094
BibTeX
@article{Schwartz2024,
author = {Schwartz, Elizabeth K C and De Aquino, Joao P and Sofuoglu, Mehmet},
title = {Glial modulators as novel therapeutics for comorbid pain and opioid use disorder},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16094}
}
EUVIMED